NCT05286411

Brief Summary

Morbidity and mortality reviews represent an opportunity to discuss adverse events and healthcare issues. Aim is to report the first experience of implementing a standardized procedure of morbidity and mortality reviews, and assess its impact on quality improvement.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
13

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2019

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2019

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2020

Completed
2.1 years until next milestone

First Submitted

Initial submission to the registry

March 9, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

March 18, 2022

Completed
Last Updated

April 5, 2022

Status Verified

March 1, 2022

Enrollment Period

12 months

First QC Date

March 9, 2022

Last Update Submit

March 25, 2022

Conditions

Keywords

morbidity and mortality reviewsimplementationquality improvementpatient safety

Outcome Measures

Primary Outcomes (1)

  • Process assessment

    evaluation of the number of MMRs, numbers and categories of identified contributing factors, number and types of recommendations and number and types of implemented recommendations.

    one year

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who underwent a curative surgical procedure for a digestive cancer in our department during the study period and who presented severe adverse events in 90 post operative day

You may qualify if:

  • severe adverse events defined as postoperative morbidity \> 3a according to the Clavien Dindo grading system
  • within the first 90 postoperative days of surgery
  • Cases discussed in a morbidity and mortality review

You may not qualify if:

  • Cases not discussed in a morbidity mortality review

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institute of Oncology

Rabat, 10090, Morocco

Location

Related Publications (4)

  • Houssaini K, Lahnaoui O, Souadka A, Majbar MA, Ghanam A, El Ahmadi B, Belkhadir Z, Amrani L, Mohsine R, Benkabbou A. Contributing factors to severe complications after liver resection: an aggregate root cause analysis in 105 consecutive patients. Patient Saf Surg. 2020 Sep 29;14:36. doi: 10.1186/s13037-020-00261-7. eCollection 2020.

    PMID: 33014137BACKGROUND
  • Souadka A, Benkabbou A, Al Ahmadi B, Boutayeb S, Majbar MA. Preparing African anticancer centres in the COVID-19 outbreak. Lancet Oncol. 2020 May;21(5):e237. doi: 10.1016/S1470-2045(20)30216-3. Epub 2020 Apr 3. No abstract available.

    PMID: 32251622BACKGROUND
  • Souadka A, Majbar MA, Essangri H, Amrani L, Benkabbou A, Mohsine R, Souadka A. Functional outcomes over time following perineal pseudocontinent colostomy reconstruction after abdominoperineal resection for ultralow rectal adenocarcinoma. J Surg Oncol. 2020 Sep;122(4):753-759. doi: 10.1002/jso.26074. Epub 2020 Jun 20.

    PMID: 32563198BACKGROUND
  • Majbar MA, Courtot L, Dahbi-Skali L, Rafik A, Jouppe PO, Moussata D, Benkabbou A, Mohsine R, Ouaissi M, Souadka A. Two-step pull-through colo-anal anastomosis aiming to avoid stoma in rectal cancer surgery: A "real life" study in a developing country. J Visc Surg. 2022 Jun;159(3):187-193. doi: 10.1016/j.jviscsurg.2021.04.004. Epub 2021 Jun 4.

    PMID: 34092526BACKGROUND

Study Officials

  • Oumayma Lahnaoui, MD

    National Institute of Oncology

    PRINCIPAL INVESTIGATOR
  • Anass Majbar, MD

    National Institute of Oncology

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor MA Majbar

Study Record Dates

First Submitted

March 9, 2022

First Posted

March 18, 2022

Study Start

January 1, 2019

Primary Completion

December 31, 2019

Study Completion

January 31, 2020

Last Updated

April 5, 2022

Record last verified: 2022-03

Locations